TABLE 6 ] .
Mean Change in θ | LVRS (n = 9) | Control Subjects (n = 10) | Between-Group Difference in Change from Baseline | P Valuea | BLVR (n = 7) | Control Subjects (n = 10) | Between-Group Difference in Change from Baseline | P Valuea | All Successful LVR (n = 16) | Control Subjects (n = 10) | Between-Group Difference in Mean Change From Baseline | P Valuea |
θRC | −17.3 ± 13.5 | 16.1 ± 14.3 | 33.3 (−75.0 to 8.4) | .03 | −42.4 ± 11.5 | 16.1 ± 14.3 | 58.4 (−100.3 to −16.6) | .003 | −28.2 ± 9.4 | 16.1 ± 14.3 | 44.3 (−78.0 to −10.6) | .003 |
θRC treated side | −25.4 ± 14.2 | 17.8 ± 12.0 | 43.2 (−82.2 to −4.3) | .04 | −49.6 ± 13.7 | 17.8 ± 12.0 | 67.40 (−106.6 to −28.2) | .001 | −36.0 ± 10.1 | 17.8 ± 12.0 | 53.8 (−86.8 to −20.9) | .003 |
θRC untreated side | −11.9 ± 13.7 | −5.4 ± 18.7 | 6.5 (−56.4 to 43.4) | .96 | −25.3 ± 17.8 | −5.4 ± 18.7 | 19.9 (−77.3 to 37.4) | .31 | −17.7 ± 10.7 | −5.4 ± 18.7 | 12.4 (−53.6 to 28.9) | .62 |
θDIA | 28.9 ± 8.0 | −6.0 ± 16.4 | 34.8 (−5.1 to 74.8) | .008 | 28.0 ± 14.6 | −6.0 ± 16.4 | 34.0 (−15.4 to 83.3) | .05 | 28.5 ± 7.5 | −6.0 ± 16.4 | 34.5 (1.42 to 67.5) | .007 |
θDIA treated side | 32.8 ± 7.5 | −11.2 ± 15.1 | 44.0 (7.2 to 80.8) | .008 | 30.0 ± 17.1 | −11.2 ± 15.1 | 41.2 (−7.8 to 90.3) | .07 | 31.6 ± 8.3 | −11.2 ± 15.1 | 42.8 (10.2 to 75.4) | .008 |
θDIA untreated side | 14.8 ± 11.3 | −1.2 ± 4.4 | 16.0 (−15.7 to 47.6) | .11 | 16.4 ± 16.9 | −1.2 ± 4.4 | 17.6 (−14.2 to 49.4) | .131 | 14.8 ± 11.3 | −1.2 ± 4.4 | 16.0 (−15.7 to 47.6) | .13 |